Triple Therapy Versus Biologic Therapy for Active Rheumatoid Arthritis: A Cost-Effectiveness Analysis.
暂无分享,去创建一个
N. Bansback | E. Keystone | J. O'dell | A. Anis | T. Mikuls | M. Brophy | C. Phibbs | S. Leatherman | Huiying Sun | J. O’dell
[1] J. O'dell,et al. Therapies for Active Rheumatoid Arthritis after Methotrexate Failure , 2017 .
[2] K. Michaud,et al. Cost‐Effectiveness of Triple Therapy Versus Etanercept Plus Methotrexate in Early Aggressive Rheumatoid Arthritis , 2016, Arthritis care & research.
[3] C. Bombardier,et al. Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying antirheumatic drugs for rheumatoid arthritis: abridged Cochrane systematic review and network meta-analysis , 2016, British Medical Journal.
[4] Anita Patel,et al. Tumour necrosis factor inhibitors versus combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis: TACIT non-inferiority randomised controlled trial , 2015, BMJ : British Medical Journal.
[5] C. Spettell,et al. Use of Oral and Subcutaneous Methotrexate in Rheumatoid Arthritis Patients in the United States , 2014, Arthritis care & research.
[6] M. Neovius,et al. Cost-effectiveness of infliximab versus conventional combination treatment in methotrexate-refractory early rheumatoid arthritis: 2-year results of the register-enriched randomised controlled SWEFOT trial , 2014, Annals of the rheumatic diseases.
[7] E. Arias. United States life tables, 2009. , 2014, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.
[8] J. Lewis,et al. Trends in the Use of Biologic Agents Among Rheumatoid Arthritis Patients Enrolled in the US Medicare Program , 2013, Arthritis care & research.
[9] R. Vollenhoven,et al. Rheumatoid arthritis: Triple therapy or etanercept after methotrexate failure in RA? , 2013, Nature Reviews Rheumatology.
[10] Myrna M. Khan,et al. A retrospective cohort study: 10-year trend of disease-modifying antirheumatic drugs and biological agents use in patients with rheumatoid arthritis at Veteran Affairs Medical Centers , 2013, BMJ Open.
[11] H. Shin,et al. Deletion variants of RABGAP1L, 10q21.3, and C4 are associated with the risk of systemic lupus erythematosus in Korean women. , 2013, Arthritis and rheumatism.
[12] Jeffrey R Curtis,et al. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial. , 2012, Arthritis and rheumatism.
[13] Jeffrey R Curtis,et al. 2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis , 2012, Arthritis care & research.
[14] F. Wolfe,et al. Treatment and nontreatment predictors of health assessment questionnaire disability progression in rheumatoid arthritis: A longitudinal study of 18,485 patients , 2011, Arthritis care & research.
[15] M. Suarez‐Almazor,et al. A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview , 2009, Canadian Medical Association Journal.
[16] M. Liang,et al. Treatment of Very Early Rheumatoid Arthritis With Symptomatic Therapy, Disease-Modifying Antirheumatic Drugs, or Biologic Agents , 2009, Annals of Internal Medicine.
[17] J. Sharp,et al. Estimation of a numerical value for joint damage-related physical disability in rheumatoid arthritis clinical trials , 2009, Annals of the rheumatic diseases.
[18] M. Wörnert,et al. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial , 2009, The Lancet.
[19] Alan Brennan,et al. Biologic drugs for rheumatoid arthritis in the Medicare program: a cost-effectiveness analysis. , 2008, Arthritis and rheumatism.
[20] Michael M Ward,et al. Measuring function in rheumatoid arthritis: Identifying reversible and irreversible components. , 2006, Arthritis and rheumatism.
[21] R. Willke,et al. Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report. , 2005, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[22] Stephen Joel Coons,et al. US Valuation of the EQ-5D Health States: Development and Testing of the D1 Valuation Model , 2005, Medical care.
[23] A. McMahon,et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial , 2004, The Lancet.
[24] J. Ware,et al. Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. , 2000, Arthritis and rheumatism.
[25] Andrew H. Briggs,et al. Handling Uncertainty in Cost-Effectiveness Models , 2000, PharmacoEconomics.
[26] D Polsky,et al. Confidence intervals for cost-effectiveness ratios: a comparison of four methods. , 1997, Health economics.
[27] R. Chang,et al. A cost-effectiveness analysis of total hip arthroplasty for osteoarthritis of the hip. , 1997, JAMA.
[28] J. O'dell,et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. , 1996, The New England journal of medicine.
[29] J F Fries,et al. The health assessment questionnaire 1992: status and review. , 1992, Arthritis care and research : the official journal of the Arthritis Health Professions Association.
[30] Milton C Weinstein,et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices--Modeling Studies. , 2003, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[31] M. Prevoo,et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. , 1995, Arthritis and rheumatism.